Solid Biosciences Inc.

NasdaqGS:SLDB Stock Report

Market Cap: US$339.3m

Solid Biosciences Future Growth

Future criteria checks 2/6

Solid Biosciences's earnings are forecast to decline at 9.1% per annum while its annual revenue is expected to grow at 64.9% per year. EPS is expected to grow by 12.5% per annum. Return on equity is forecast to be -80% in 3 years.

Key information

-9.1%

Earnings growth rate

12.5%

EPS growth rate

Biotechs earnings growth24.9%
Revenue growth rate64.9%
Future return on equity-80.0%
Analyst coverage

Good

Last updated15 Jul 2024

Recent future growth updates

Recent updates

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth

Jul 26
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth

Buy Solid Biosciences: Unpacking Its Main Value Driver

Apr 10

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Jan 17

Solid Biosciences to acquire gene therapy company AavantiBio

Sep 30

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Apr 30
Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Apr 28
Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Mar 17
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Oct 28
Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Jul 13
We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Soild Bio sinks 13% after Sarepta data misses goal

Jan 08

Solid Biosciences launches $90M private placement

Dec 11

Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data

Nov 10

Earnings and Revenue Growth Forecasts

NasdaqGS:SLDB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262-148-214-1945
12/31/20254-122-108-1217
12/31/20243-103-60-598
3/31/2024N/A-90-93-91N/A
12/31/2023N/A-96-96-94N/A
9/30/2023N/A-91-110-108N/A
6/30/2023N/A-90-113-110N/A
3/31/20236-91-102-99N/A
12/31/20228-86-101-98N/A
9/30/202211-89-87-84N/A
6/30/202215-87-85-82N/A
3/31/202212-81-85-84N/A
12/31/202114-72-79-78N/A
9/30/202110-75-56-56N/A
6/30/20217-78-53-53N/A
3/31/20213-78-49-49N/A
12/31/2020N/A-88-57-57N/A
9/30/2020N/A-99-81-79N/A
6/30/2020N/A-107-85-83N/A
3/31/2020N/A-114-99-96N/A
12/31/2019N/A-117-97-93N/A
9/30/2019N/A-107-98-93N/A
6/30/2019N/A-97-96-89N/A
3/31/2019N/A-89-88-79N/A
12/31/2018N/A-75-78-70N/A
9/30/2018N/A-67-69-63N/A
6/30/2018N/A-62-63-57N/A
3/31/2018N/A-55-53-50N/A
12/31/2017N/A-39N/A-43N/A
9/30/2017N/A-29N/A-35N/A
12/31/2016N/A-17N/A-20N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLDB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SLDB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SLDB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SLDB's revenue (64.9% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: SLDB's revenue (64.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SLDB is forecast to be unprofitable in 3 years.


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.